What clinicians need to know about antioestrogen resistance in breast cancer therapy

被引：38

作者：

Milano, Amalia ^{[1
]}

Dal Lago, Lissandra ^{[1
]}

Sotiriou, Christos ^{[1
]}

Piccart, Martine ^{[1
]}

Cardoso, Fatima ^{[1
]}

机构：

[1] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 16期

关键词：

breast cancer; tamoxifen-resistance; predictive marker; AIB1; HER-2; oestrogen receptor; progesterone receptor; cox-2; cyclin E; UPA/PAI-1;

D O I：

10.1016/j.ejca.2006.06.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positive patients. Unfortunately, despite high ER tumour levels in a tumour, resistance to endocrine therapy, either de novo or acquired after prolonged treatment, can occur. In this review, we will try to summarise the postulated mechanisms of hormonal-resistance, namely, the role of co-regulators and the crosstalk between the HER-2, IGF-IR, Cox-2 and ER pathways. Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：2692 / 2705

页数：14

共 128 条

[101] c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis [J].

Pinto, AE ;

André, S ;

Pereira, T ;

Nóbrega, S ;

Soares, J .

ANNALS OF ONCOLOGY, 2001, 12 (04) :525-533

[102] Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms [J].

Porter, DC ;

Zhang, N ;

Danes, C ;

McGahren, MJ ;

Harwell, RM ;

Faruki, S ;

Keyomarsi, K .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (18) :6254-6269

[103] Limits of predictive models using microarray data for breast cancer clinical treatment outcome [J].

Reid, JF ;

Lusa, L ;

De Cecco, L ;

Coradini, D ;

Veneroni, S ;

Daidone, MG ;

Gariboldi, M ;

Pierotti, MA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (12) :927-930

[104]

RINEHART JJ, 2002, P AN M AM SOC CLIN, V21, P11

[105]

Ristimäki A, 2002, CANCER RES, V62, P632

[106] Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance [J].

Schiff, R ;

Massarweh, SA ;

Shou, J ;

Bharwani, L ;

Mohsin, SK ;

Osborne, CK .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :331S-336S

[107]

Schiff R, 2003, CLIN CANCER RES, V9, p447S

[108] BCL-2 EXPRESSION IS ASSOCIATED WITH LYMPH-NODE METASTASIS IN HUMAN DUCTAL BREAST-CARCINOMA [J].

SIERRA, A ;

LLOVERAS, B ;

CASTELLSAGUE, X ;

MORENO, L ;

GARCIARAMIREZ, M ;

FABRA, A .

INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (01) :54-60

[109]

Sjögren S, 1998, J CLIN ONCOL, V16, P462

[110] Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen [J].

Smith, CL ;

Nawaz, Z ;

OMalley, BW .

MOLECULAR ENDOCRINOLOGY, 1997, 11 (06) :657-666

← 4 5 6 7 8 9 10 11 12 13 →